Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Bioavailability of Sulfatinib Capsules in Healthy Chinese Males
NCT03483259Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of surufatinib in neuroendocrine tumors (NETs) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Curve, Maximum Observed Plasma Concentration and 3 more. Started Apr 2018; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03483259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483259.